CytomX Therapeutics (CTMX) Competitors $0.84 -0.01 (-0.84%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CTMX vs. NGNE, CMPX, AVIR, CGC, ACIU, BNTC, CCCC, FHTX, LFCR, and URGNShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Neurogene (NGNE), Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Canopy Growth (CGC), AC Immune (ACIU), Benitec Biopharma (BNTC), C4 Therapeutics (CCCC), Foghorn Therapeutics (FHTX), Lifecore Biomedical (LFCR), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Neurogene Compass Therapeutics Atea Pharmaceuticals Canopy Growth AC Immune Benitec Biopharma C4 Therapeutics Foghorn Therapeutics Lifecore Biomedical UroGen Pharma CytomX Therapeutics (NASDAQ:CTMX) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk. Which has more volatility and risk, CTMX or NGNE? CytomX Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Does the MarketBeat Community favor CTMX or NGNE? CytomX Therapeutics received 346 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 65.38% of users gave CytomX Therapeutics an outperform vote. CompanyUnderperformOutperformCytomX TherapeuticsOutperform Votes37265.38% Underperform Votes19734.62% NeurogeneOutperform Votes26100.00% Underperform VotesNo Votes Do analysts prefer CTMX or NGNE? CytomX Therapeutics presently has a consensus price target of $5.77, indicating a potential upside of 587.20%. Neurogene has a consensus price target of $60.83, indicating a potential upside of 266.47%. Given CytomX Therapeutics' higher possible upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Neurogene 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is CTMX or NGNE more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Neurogene's net margin of 0.00%. Neurogene's return on equity of -32.81% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics10.96% -41.47% 8.11% Neurogene N/A -32.81%-27.96% Which has preferable valuation and earnings, CTMX or NGNE? CytomX Therapeutics has higher revenue and earnings than Neurogene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$101.21M0.65-$570K$0.174.94NeurogeneN/AN/A-$36.32MN/AN/A Does the media prefer CTMX or NGNE? In the previous week, CytomX Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for CytomX Therapeutics and 0 mentions for Neurogene. CytomX Therapeutics' average media sentiment score of 0.94 beat Neurogene's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Overall Sentiment CytomX Therapeutics Positive Neurogene Neutral Do insiders and institutionals have more ownership in CTMX or NGNE? 67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 7.0% of CytomX Therapeutics shares are owned by insiders. Comparatively, 9.9% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryCytomX Therapeutics beats Neurogene on 9 of the 16 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.74M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio4.949.8789.3417.36Price / Sales0.65309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book-1.186.055.314.79Net Income-$570,000.00$154.90M$122.54M$225.00M7 Day Performance-5.34%-0.32%0.59%2.62%1 Month Performance-22.94%0.43%2.55%3.81%1 Year Performance-48.47%3.08%25.29%20.10% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.6352 of 5 stars$0.84-0.8%$5.77+587.2%-48.5%$65.74M$101.21M4.94170NGNENeurogene2.7286 of 5 stars$18.30-6.5%$60.83+232.4%-44.8%$271.85M$925,000.000.0090Gap DownCMPXCompass Therapeutics3.1594 of 5 stars$1.97+11.3%$11.80+499.0%+87.1%$271.05M$850,000.00-5.3220Short Interest ↑AVIRAtea Pharmaceuticals3.8788 of 5 stars$3.13-4.3%$6.88+119.8%-5.6%$264.37M$351.37M-1.5170Positive NewsGap UpCGCCanopy Growth3.2078 of 5 stars$2.38-2.9%$3.50+47.1%-50.1%$259.28M$280.50M-0.483,150Positive NewsACIUAC Immune2.2523 of 5 stars$2.62-3.7%$12.00+358.0%-35.4%$259.22M$40.97M-5.70140Positive NewsBNTCBenitec Biopharma3.0131 of 5 stars$10.44-5.1%$24.43+134.0%+261.4%$242.38M$80,000.00-3.6820Positive NewsGap DownCCCCC4 Therapeutics2.0809 of 5 stars$3.42-6.8%$10.67+211.9%-33.3%$241.41M$33.67M-2.01150Positive NewsGap DownFHTXFoghorn Therapeutics2.7018 of 5 stars$4.28-0.5%$13.80+222.4%+12.2%$237.94M$25.52M-2.23120Positive NewsGap DownLFCRLifecore Biomedical1.6078 of 5 stars$6.41+1.9%$8.00+24.8%-7.8%$237.33M$130.86M80.13690Short Interest ↑URGNUroGen Pharma3.9511 of 5 stars$10.11-1.3%$43.70+332.2%-30.5%$237.12M$89.36M-3.21200Positive NewsGap Down Related Companies and Tools Related Companies Neurogene Competitors Compass Therapeutics Competitors Atea Pharmaceuticals Competitors Canopy Growth Competitors AC Immune Competitors Benitec Biopharma Competitors C4 Therapeutics Competitors Foghorn Therapeutics Competitors Lifecore Biomedical Competitors UroGen Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTMX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTMX Stock Alerts